// App-Quantinova.ai

3645 : Omeprazole, A Potent Cyp 2c19 Inhibitor, Does Not Alter The Pharmacokinetics Or Platelet Aggregation Of Asa And Dipyridamole In Combination

Researchers

Presenter

  • Rolf Rolf-Stefan

Principal Investigators

  • Cam Vandermaelen

  • Michael Schobelock

  • Wolfgang Eisert

Medical Centers

  • Celerion, St-Laurent Montreal, QC

  • Inc, Ridgefield, CT

  • Inc, Columbus, OH

Locations

  • United States

  • Canada

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Stroke

Biomarkers

  • Cytochrome P450 2C19

Drug/Treatment

  • dipyridamole

  • Clopidogrel bisulfate

  • Omeprazole

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • open label

  • randomized

  • cross over

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved